Literature DB >> 24003247

Immunosuppressive drug therapy.

Choli Hartono1, Thangamani Muthukumar, Manikkam Suthanthiran.   

Abstract

The first successful kidney transplantation between monozygotic identical twins did not require any immunosuppressive drugs. Clinical application of azathioprine and glucocorticosteroids allowed the transfer of organs between genetically disparate donors and recipients. Transplantation is now the standard of care, a life-saving procedure for patients with failed organs. Progress in our understanding of the immunobiology of rejection has been translated to the development of immunosuppressive agents targeting T cells, B cells, plasma cells, costimulatory signals, complement products, and antidonor antibodies. Modern immunopharmacologic interventions have contributed to the clinical success observed following transplantation but challenges remain in personalizing immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24003247      PMCID: PMC3753725          DOI: 10.1101/cshperspect.a015487

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  68 in total

1.  A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.

Authors:  D C Brennan; K Flavin; J A Lowell; T K Howard; S Shenoy; S Burgess; S Dolan; J M Kano; M Mahon; M A Schnitzler; R Woodward; W Irish; G G Singer
Journal:  Transplantation       Date:  1999-04-15       Impact factor: 4.939

2.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

3.  Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.

Authors:  J O Medina Pestana; J M Grinyo; Y Vanrenterghem; T Becker; J M Campistol; S Florman; V D Garcia; N Kamar; P Lang; R C Manfro; P Massari; M D C Rial; M A Schnitzler; S Vitko; T Duan; A Block; M B Harler; A Durrbach
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

Review 4.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

Authors:  A C Webster; V W Lee; J R Chapman; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 5.  Transplantation tolerance: fooling mother nature.

Authors:  M Suthanthiran
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

6.  Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

Authors:  Lionel Rostaing; Pablo Massari; Valter Duro Garcia; Eduardo Mancilla-Urrea; Georgy Nainan; Maria del Carmen Rial; Steven Steinberg; Flavio Vincenti; Rebecca Shi; Greg Di Russo; Dolca Thomas; Josep Grinyó
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

7.  Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells.

Authors:  A Khanna; V Cairns; J D Hosenpud
Journal:  Transplantation       Date:  1999-02-27       Impact factor: 4.939

Review 8.  Mycophenolate mofetil in kidney transplantation.

Authors:  S L Lui; P F Halloran
Journal:  Curr Opin Nephrol Hypertens       Date:  1996-11       Impact factor: 2.894

9.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

10.  Rituximab and intravenous immune globulin for desensitization during renal transplantation.

Authors:  Ashley A Vo; Marina Lukovsky; Mieko Toyoda; Jennifer Wang; Nancy L Reinsmoen; Chih-Hung Lai; Alice Peng; Rafael Villicana; Stanley C Jordan
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

View more
  23 in total

1.  Urine Metabolite Profiles Predictive of Human Kidney Allograft Status.

Authors:  Karsten Suhre; Joseph E Schwartz; Vijay K Sharma; Qiuying Chen; John R Lee; Thangamani Muthukumar; Darshana M Dadhania; Ruchuang Ding; David N Ikle; Nancy D Bridges; Nikki M Williams; Gabi Kastenmüller; Edward D Karoly; Robert P Mohney; Michael Abecassis; John Friedewald; Stuart J Knechtle; Yolanda T Becker; Benjamin Samstein; Abraham Shaked; Steven S Gross; Manikkam Suthanthiran
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

2.  Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection.

Authors:  J S Young; J Chen; M L Miller; V Vu; C Tian; J J Moon; M-L Alegre; R Sciammas; A S Chong
Journal:  Am J Transplant       Date:  2016-04-04       Impact factor: 8.086

Review 3.  Nanoparticles and direct immunosuppression.

Authors:  Terrika A Ngobili; Michael A Daniele
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

Review 4.  Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases.

Authors:  Gauthami Pulivendala; Swarna Bale; Chandraiah Godugu
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 5.  Direct detection of Strongyloides infection via molecular and antigen detection methods.

Authors:  Dinesh Balachandra; Hussain Ahmad; Norsyahida Arifin; Rahmah Noordin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-07-29       Impact factor: 3.267

Review 6.  Adaptive Immunity Dysregulation in Acute Coronary Syndromes: From Cellular and Molecular Basis to Clinical Implications.

Authors:  Davide Flego; Giovanna Liuzzo; Cornelia M Weyand; Filippo Crea
Journal:  J Am Coll Cardiol       Date:  2016-11-08       Impact factor: 24.094

Review 7.  Oncolytic Virotherapy: A Contest between Apples and Oranges.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2017-04-06       Impact factor: 11.454

8.  Novel peptide-based inhibitor for targeted inhibition of T cell function.

Authors:  Ashna Gauthaman; Rini Jacob; Sneha Pasupati; Abarna Rajadurai; C George Priya Doss; Anbalagan Moorthy
Journal:  J Cell Commun Signal       Date:  2021-12-01       Impact factor: 5.908

Review 9.  Immunomodulatory Nanosystems.

Authors:  Xiangru Feng; Weiguo Xu; Zhongmin Li; Wantong Song; Jianxun Ding; Xuesi Chen
Journal:  Adv Sci (Weinh)       Date:  2019-06-21       Impact factor: 16.806

Review 10.  On the role of the immunoproteasome in transplant rejection.

Authors:  Michael Basler; Jun Li; Marcus Groettrup
Journal:  Immunogenetics       Date:  2018-09-15       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.